Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs)

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 10, 2014, Pages 1869-1871

  Cunha, B A ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COST CONTROL; DRUG COST; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; ECONOMICS; FEMALE; ISOLATION AND PURIFICATION; MALE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84911005060     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2113-z     Document Type: Letter

References (25)

1. Seaton RA, Johal S, Coia JE et al (2014) Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect Dis 33:305–311
2. Gould FK, Brindle R, Chadwick PR et al (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63:849–861
3. Dryden M, Andrasevic AT, Bassetti M et al (2010) A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 16(Suppl 1):3–30
4. Seaton RA, Sharp E, Bezlyak V et al (2011) Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents 38:243–248
5. Chapman ALN, Seaton RA, Cooper MA et al (2012) Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 67:1053–1062
6. Cunha BA (2001) Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Am J Med 111:412–413
7. Cunha BA (2004) Empiric oral monotherapy for hospitalized patients with community-acquired pneumonia: an idea whose time has come. Eur J Clin Microbiol Infect Dis 23:78–81
8. Cunha BA (2005) Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11:33–42
9. Cunha BA (2014) Cephalexin remains the preferred antibiotic for uncomplicated cellulitis: revisited. J Chemother 26:65–66
10. Cunha BA (1998) Factors in antibiotic selection for hospital formularies (part I). Hosp Formul 33:558–572
11. Cunha BA (2008) Oral and i.v.-to-p.o. switch antibiotic therapy of hospitalized patients with serious infections. Scand J Infect Dis 40:1004–1006
12. Cunha BA (2006) Oral antibiotic therapy of serious systemic infections. Med Clin North Am 90:1197–1222
13. Rubinstein E, Keynan Y (2013) Short-course therapy for severe infections. Int J Antimicrob Agents 42:S22–S24
14. Lidji M, Rubinstein E, Samra H (1978) Bacterial endocarditis on a prosthetic valve. Oral treatment with amoxicillin. Chest 74:224–225
15. Cunha BA (2005) Oral antibiotic treatment of MRSA infections. J Hosp Infect 60:88–90
16. Cunha BA (ed) (2013) Antibiotic essentials, 12th edn. Jones and Bartlett, Sudbury, pp 8–16, 132–135, 595–597, 647–648, 680–682
17. Kucers A, Crowe SM, Grayson ML et al (eds) (1997) Kucers’ the use of antibiotics, 4th edn. Butterworth-Heinemann, Oxford, pp 719–763
18. McKinnon PS, Sorensen SV, Liu LZ, Itani KM (2006) Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40:1017–1023
19. Schwartz BS, Graber CJ, Diep BA et al (2009) Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis 48:1483–1484
20. Cunha BA (1997) Problems arising in antimicrobial therapy due to false susceptibility testing. J Chemother 9:25–35
21. Cunha BA (2010) Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 35:517–518
22. Cunha BA (2013) Minocycline, often forgotten but preferred to trimethoprim–sulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int J Antimicrob Agents 42:497–499
23. Gray A, Dryden M, Charos A (2012) Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother 67:2297–2302
24. Dryden M, Saeed K, Townsend R et al (2012) Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother 67:2289–2296
25. Cunha BA (2014) Minocycline is a reliable and effective oral option to treat meticillin-resistant Staphylococcus aureus skin and soft-tissue infections, including doxycycline treatment failures. Int J Antimicrob Agents 43:386–387